Brown J H, Douglas A F, Murphy B G, Hill C M, McNamee P T, Nelson W E, Doherty C C
Mary G McGeown Regional Nephrology Unit, Belfast City Hospital, UK.
Nephrol Dial Transplant. 1998 Feb;13(2):443-8. doi: 10.1093/oxfordjournals.ndt.a027844.
Progressive deterioration in renal function occurs in 20-50% of patients with idiopathic membranous nephropathy (IMN). Several treatment regimens have been used to reverse this with varying effect and toxicity.
Thirteen patients (10 males, 3 females, median age 56 years) with IMN and progressive renal failure were treated with oral prednisolone 20-60 mg/day and azathioprine 1.3-2.7 mg/kgBW/day. All patients were followed up for a minimum of 2 years with a median follow-up of 73 months (range 24-103 months).
Ten patients responded to treatment with a fall in serum creatinine and renal function stabilized in the remainder. Two patients relapsed, one of whom responded to an increase in immunosuppression, the other is now on dialysis. Proteinuria has significantly reduced in 10 patients, and only four patients still have nephrotic-range proteinuria. Mean (+/- SE) peak pretreatment serum creatinine of 229 (+/- 161) mumol/l and urinary protein of 11.8 (+/- 1.8) g/24 have fallen to 163 (+/- 65) mumol/l and 3.25 (+/- 1.0) g/24 h after 12 months treatment (P < 0.005, Wilcoxon matched pairs test). Immunosuppressive treatment has been successfully withdrawn in four patients after intervals ranging from 12 to 60 months. Adverse effects, which occurred in 10 patients, have been mild and have not led to treatment withdrawal though dose reductions have been necessary in some patients.
Oral prednisolone and low-dose azathioprine is an effective therapy for progressing renal failure due to IMN, and induces remission of nephrotic syndrome. Side-effects are less than other immunosuppressive regimens.
20%至50%的特发性膜性肾病(IMN)患者会出现肾功能进行性恶化。已采用多种治疗方案来逆转这种情况,但其疗效和毒性各不相同。
13例(10例男性,3例女性,中位年龄56岁)患有IMN且肾功能进行性衰竭的患者,接受口服泼尼松龙20至60毫克/天和硫唑嘌呤1.3至2.7毫克/千克体重/天的治疗。所有患者至少随访2年,中位随访时间为73个月(范围24至103个月)。
10例患者对治疗有反应,血清肌酐下降,其余患者肾功能稳定。2例患者复发,其中1例对增加免疫抑制治疗有反应,另1例目前正在接受透析。10例患者的蛋白尿显著减少,只有4例患者仍有肾病范围的蛋白尿。治疗12个月后,平均(±标准误)治疗前血清肌酐峰值229(±161)微摩尔/升和尿蛋白11.8(±1.8)克/24小时已降至163(±65)微摩尔/升和3.25(±1.0)克/24小时(P<0.005,Wilcoxon配对检验)。4例患者在12至60个月的不同间隔后成功停用免疫抑制治疗。10例患者出现不良反应,均较轻微,虽部分患者需要减少剂量,但未导致治疗中断。
口服泼尼松龙和低剂量硫唑嘌呤是治疗IMN所致肾功能进行性衰竭的有效疗法,可诱导肾病综合征缓解。副作用比其他免疫抑制方案少。